Previous 10 | Next 10 |
Today, we will see why Genmab (GMAB) is an attractive biotech pick in March 2020. Company overview Genmab is a dual-listed biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. The company was founded in 19...
In the coronavirus-fueled bear market, Horizon Therapeutics (NASDAQ: HZNP) offers an attractive investment opportunity for healthcare investors . The specialty pharma delivered $1.3 billion in revenue in 2019 from a diverse portfolio of products. More importantly, it posted net income ...
Today, we will see why Selecta Biosciences (SELB) is an attractive pick in March 2020. Company overview Selecta Biosciences is a clinical-stage biopharmaceutical company focused on overcoming immunogenicity associated with biologic therapies. The company is deploying its proprietary plat...
Horizon Therapeutics (Nasdaq: HZNP) and Willis Towers Watson (Nasdaq: WLTW) are partnering with Willis Tower to light the antennas of the Willis Tower on Feb. 29 in recognition of Rare Disease Day and to raise awareness of the crucial need to identify new medicines for the 30 million people l...
Horizon Therapeutics plc (Nasdaq: HZNP) today announced a $1 million commitment over five years to establish the #RAREis scholarship, a program that will be made available by the EveryLife Foundation for Rare Diseases. The #RAREis scholarship will support the pursuit of life enrichment ac...
Image source: The Motley Fool. Horizon Therapeutics PLC (NASDAQ: HZNP) Q4 2019 Earnings Call Feb 26, 2020 , 8:00 a.m. ET Operator Continue reading
On Wednesday morning, Horizon Therapeutics (NASDAQ: HZNP) announced its fourth-quarter and full-year financial results. Thanks to strong sales of its top drug, a gout treatment known as Krystexxa, the company beat both its revenue and earnings estimates. Fourth-quarter revenue came in at $3...
Horizon Pharma plc (HZNP) Q4 2019 Earnings Conference Call February 26, 2020 8:00 AM ET Company Participants Tina Ventura - Senior Vice President, Investor Relations Tim Walbert - Chairman, President and Chief Executive Officer Liz Thompson - Group Vice President, Clinical Develo...
The following slide deck was published by Horizon Therapeutics Public Limited Company in conjunction with their 2019 Q4 earnings Read more ...
Horizon Therapeutics ( HZNP ) Q4 results : More news on: Horizon Therapeutics Public Limited Company, Healthcare stocks news, Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Horizon Therapeutics Public Limited Company Company Name:
HZNP Stock Symbol:
NASDAQ Market:
Horizon Therapeutics Public Limited Company Website:
Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...
Horizon Therapeutics Public Limited Company (HZNP) is expected to report $1.22 for Q3 2023
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOM...